Journal
RSC MEDICINAL CHEMISTRY
Volume 11, Issue 8, Pages 876-884Publisher
ROYAL SOC CHEMISTRY
DOI: 10.1039/d0md00154f
Keywords
-
Funding
- ITN Accelerated Early stage drug dIScovery (AEGIS) [675555]
- National Institute of Health (NIH) [2R01GM097082-05]
- European Lead Factory (IMI) [115489]
- Qatar National Research Foundation [NPRP6-065-3-012]
- COFUNDs ALERT [665250]
- Prominent [754425]
- KWF Kankerbestrijding grant [10504]
- Indonesian Endowment Fund for Education (Lembaga Pengelola Dana Pendidikan)
Ask authors/readers for more resources
Covalent inhibitors are recognized as an important component in drug discovery and therapeutics. Since the first appearance of covalent inhibitors in the late 18th century, the field has advanced significantly and currently about 30% of the marketed drugs are covalent inhibitors. The numerous advantages of covalent inhibitors are counteracting the initial concerns regarding potential off-target toxicity. Thus, continuous research, especially for cancer targets is reported. The aim of this review is to provide a short historic overview and focus on recently developed covalent inhibitors (2011-2019), including structural aspects and examples on challenging targets.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available